Ethinylestradiol/levonorgestrel - Gynetics

Drug Profile

Ethinylestradiol/levonorgestrel - Gynetics

Alternative Names: Levonorgestrel/ethinylestradiol - Gynetics; Preven

Latest Information Update: 18 Jan 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gynetics
  • Developer Gynetics; Nonindustrial source; Shire
  • Class Alkylated estrogenic steroids; Contraceptives; Hormonal replacements; Norpregnanes; Norpregnatrienes; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 18 Jan 2000 Roberts Pharmaceutical has been merged into Shire Pharmaceuticals Group
  • 10 Nov 1999 Launched for Contraception/Pregnancy (Prevention) in Canada (PO)
  • 12 May 1999 Roberts Pharmaceutical has received marketing rights in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top